

ПЕРЕЛІК ПОСИЛАНЬ

1. Хабриев Р.У., Куликов А.Ю., Аринина Е.Е. Методологические основы фармакоэкономического анализа. – М.: ОАО «Издательство «Медицина», 2011. – 128 с.
2. Institute for Operations Research and the Management Sciences. Informs online [Электронный ресурс]: Режим доступа: <http://www.informs.org>.
3. TreeAge Pro 2014 User's Manual [Электронный ресурс]: Режим доступа: <http://installers.treeagesoftware.com/treeagepro/14.1.0/PDF/TP-Manual-2014R1.pdf>.
4. Annals of Internal Medicine [Электронный ресурс]: Режим доступа: <http://annals.org/article.aspx?articleid=700846>.
5. AutoMod User's Manual [Электронный ресурс]: Режим доступа: https://www.simplan.de/images/stories/download/ENG/AutoMod_engl.pdf.
6. Arena Simulation Software [Электронный ресурс]: Режим доступа: <https://www.arenasimulation.com/industry-solutions/healthcare-simulation-software>.
7. MedCalc statistical software [Электронный ресурс]: Режим доступа: <https://www.medcalc.org/statistics.php>
8. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004; 9: 110-8.
9. Brennan A, Chick S, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15: 1295-310.
10. Mauskopf JA, Paul JE, Grant DM, et al. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics 1998; 13 (3): 277-88.
11. England W, Roberts S. Immunization to prevent insulin-dependent diabetes mellitus? The economics of genetic screening and vaccination for diabetes. Ann Intern Med 1981; 94: 395-400.
12. Анализ выживаемости [Электронный ресурс]: Режим доступа: http://www.machinelearning.ru/wiki/index.php?title=Анализ_выживаемости

13. Анализ выживаемости [Электронный ресурс]: Режим доступа: <http://www.recognition.mccme.ru/pub/RecognitionLab.html/survival.pdf>
14. England W, Roberts S. Immunization to prevent insulin-dependent diabetes mellitus? The economics of genetic screening and vaccination for diabetes. *Ann Intern Med* 1981; 94: 395-400.
15. Fineberg H. Decision trees: construction, uses, and limits. *Bull Cancer* 1980; 67: 395-404.
16. Gold MR, Siegel JE, Russell LB, et al. Cost effectiveness in health and medicine. New York: Oxford University Press, 1996.
17. Plante D, Kassirer J, Zarin D, et al. Clinical decision consultation service. *Am J Med* 1986; 80: 1169-76.
18. Scott WG, Tilyard MW, Dovey SM, et al. Roxithromycin versus cefaclor in lower respiratory tract infection. A general practice pharmacoeconomic study. *Pharmacoeconomics* 1993; 4 (2): 122-30.
19. Grinstead C, Snell J. Introduction to probability. Providence RI): American Mathematical Society, 1997.
20. Sonnenberg F, Beck J. Markov models in medical decision making: a practical guide. *Med Dec Mak* 1993; 13: 322-38.
21. Dean B, Gallivan S, Barber N, et al. Mathematical modelling of pharmacy systems. *Am J Health Syst Pharm* 1997; 54: 2491-9.
22. Eckman M, Rosand J, Knudsen K, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. *Stroke* 2003; 34: 1710-6.
23. Beck J, Pauker S. The Markov process in medical decision making. *Med Decis Making* 1983; 3: 419-58.
24. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-time agents: a systemic review and meta-analysis. *JAMA* 1997; 277 (9): 739-45.
25. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *New Engl J Med* 1996 Oct 3; 335 (14): 1001-9.

26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383-9.
27. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *New Engl J Med* 1995 Nov 16; 333 (20): 1301-7.
28. Anderson KM. A nonproportional hazards Weibull accelerated time regression model. *Biometrics* 1991; 47 (Pt A): 281-8.
29. Anderson KM, Wilson WF, Odell PM, et al. An updated coronary risk profile: a statement for health professionals. *Circulation* 1991; 83 (1 Pt B): 356-62.
30. Jönsson B, Johannesson M, Kjeksus J, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). *Eur Heart J* 1996; 17: 1001-7.
31. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. *BMJ* 1997; 315: 1577-82.
32. Milne RJ, Vander Hoorn S, Jackson RT. A predictive model of the health benefits and costs of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients. *Pharmacoeconomics* 1997; 12 (3): 384-408.
33. Mauskopf J.A. The role of cost-consequence analysis in health care decision-making / J.A. Mauskopf, J.E. Paul, D.M. Grant [et al] // *Pharmacoeconomics*. — 1998. — №13(3). — P. 277—288.
34. Berger M.L. Health care cost, quality and outcomes / M.L. Berger, K. Binglefors, E.C. Hedblom et al // *ISPOR Terms Book*. — 2003. — 264 pp.
35. Zalis'ka O.M. *Pharmacoeconomics: Textbook* / O.M. Zalis'ka // B.L. Parnovsky. Lviv: "Aphisha". — 2007. — 380 pp.
36. Fogli. A. *Social Networks and Growth* / A. Fogli, L. Veldkamp, Germs // *National Bureau of Economic Research*. — 2013. — P.47.
37. Dzyublyk I.V. *Guide of viral infections chemotherapy: Textbook for Physicians* / I.V. Dzyublyk // K. — 2004. — 176 pp.

38. Dzyublyk I.V. Influenza and its prevention: teach. manual / I.V. Dzyublyk; Shupyk Kyiv Medical Academy of Postgraduate Education Ministry of Health of Ukraine. — K., 2005. — 194 pp.
39. Dzyublyk I.V. Human bocavirus – new infectious pathogen in the etiology of acute respiratory diseases / I.V. Dzyublyk, O.V. Obertynska, Y.O. Solomko, S.O. Soloviov // Art of treatment. – 2015. – №1(2). – P.4–9.
40. Jérôme Adda Economic Activity and the Spread of Viral Diseases: Evidence from High Frequency Data / Adda Jérôme // The Quarterly Journal of Economics. – 2016. – №131. – P. 891– 941.
41. Kelly E. The Scourge of Asian Flu In utero Exposure to Pandemic Influenza and the Development of a Cohort of British Children / E. Kelly // The Journal of Human Resources. – 2011. – №46. – P. 669–694.
42. Dzyublyk I. V. Analysis of lethal causes of among HIV–infected patients of the Kiev City AIDS Center in 2013 / I.V. Dzyublyk, A.V. Yurchenko, T.V. Stepchenkova // Preventive medicine. – 2014. – № 3-4. – P. 48–49.
43. Rencher A. C. Methods of Multivariate Analysis / A. C. Rencher, W.F. Christensen / Wiley Series in Probability and Statistics 709 (3rd ed.) John Wiley & Sons. — 2012. — P. 19.
44. Hastie T. The elements of statistical learning: data mining, inference, and prediction / T. Hastie, R. Tibshirani, J.H. Friedman // 2nd ed. New York, USA: Springer. — 2009.